- $220.95m
- $140.92m
- 30
- 14
- 75
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.86 | ||
| Price to Tang. Book | 2.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -76.21% | ||
| Return on Equity | -58.75% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 27.4 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage.
Directors
- Young-Jin Kim CHM (64)
- Nevan Elam CEO (53)
- Sankaram Mantripragada CFD (62)
- Brian Roberts SVP (47)
- Philippe Fauchet IND (63)
- Wladimir Hogenhuis IND (57)
- Nerissa Kreher IND (48)
- Gilbert Labrucherie IND (50)
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 8th, 2021
- Public Since
- December 23rd, 2011
- No. of Shareholders
- 274
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 51,382,647
- Address
- 275 Shoreline Drive, Suite 500, REDWOOD CITY, 94065
- Web
- https://www.rezolutebio.com/
- Phone
- +1 6502064507
- Auditors
- Plante & Moran PLLC
Upcoming Events for RZLT
Q1 2025 Rezolute Inc Earnings Release
Similar to RZLT
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Rezolute share price?
As of Today at 22:58 UTC, shares in Rezolute are trading at $3.95. This share price information is delayed by 15 minutes.
How has the Rezolute share price performed this year?
Shares in Rezolute last closed at $3.95 and the price had moved by +83.72% over the past 365 days. In terms of relative price strength the Rezolute share price has outperformed the S&P500 Index by +46.19% over the past year.
What are the analyst and broker recommendations for Rezolute?
The overall consensus recommendation for Rezolute is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Rezolute dividend yield?
Rezolute does not currently pay a dividend.
Does Rezolute pay a dividend?
Rezolute does not currently pay a dividend.
When does Rezolute next pay dividends?
Rezolute does not currently pay a dividend.
How do I buy Rezolute shares?
To buy shares in Rezolute you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rezolute?
As of the previous close price of $3.95, shares in Rezolute had a market capitalisation of $202.96m.
Where are Rezolute shares listed?
Here are the trading details for Rezolute:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RZLT
What kind of share is Rezolute?
Based on an overall assessment of its quality, value and momentum Rezolute is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rezolute share price forecast for 2024?
The analyst consensus target price for shares in Rezolute is $10.57. That is 167.59% above the last closing price of $3.95.
Analysts covering Rezolute currently have a consensus Earnings Per Share (EPS) forecast of -$1.20 for the next financial year.
What is the trend in the Rezolute share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rezolute. Over the past six months, its share price has outperformed the S&P500 Index by +283.48%.
As of the last closing price of $3.95, shares in Rezolute were trading +115.63% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rezolute PE Ratio?
The Rezolute PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rezolute?
Rezolute's management team is headed by:
- Young-Jin Kim - CHM
- Nevan Elam - CEO
- Sankaram Mantripragada - CFD
- Brian Roberts - SVP
- Philippe Fauchet - IND
- Wladimir Hogenhuis - IND
- Nerissa Kreher - IND
- Gilbert Labrucherie - IND